-
Most Recent
Healthcare Stocks
Healthcare encompasses a wide range of organized services to prevent, treat, and diagnose medical needs and mental illnesses. The $336 billion market is expected to grow at a compound annual growth rate of 8% until 2030, demonstrating the necessity of adequate healthcare. Healthcare companies, ranging from retailer CVS to insurance giant UnitedHealth, provide these services to a massive customer base.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
7 Dependable Dividend Stocks for Long-Term Income
Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets.
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth.
Other industries you might be interested in
Recent Healthcare Stocks Articles
3 Healthcare Stocks Ready for a Breather
It's the hottest sector in the S&P 500 so far this year, and that means some big-name pullbacks are likely. Here are three likely candidates.
Biotech Movers: Keryx Jumps, Sarepta Slips
Among last week's highlights, Keryx jumps on a solid Phase III trial, Sarepta gets pounded from a fake tweet and Halozyme suffers from analyst downgrades.
It’s an ETF Picker’s Market
In some sectors, it just doesn’t pay to go stock shopping when you can buy the ETF instead. But that's some -- not all. Here are a few examples.
Keryx: An Important Biotech Reality Check in 5, 4, 3 …
This stock's tripling in the past month is your prototypical biotech "win." But if you don't lock in your gains now, you don't understand the game.
Biotech Movers: Arena Gets Warned, MAP Gets an Offer
Among last week's highlights, Europe raises questions about Arena's obesity drug, Belviq, and Allergan offers $958 million for MAP Pharmaceuticals.
10 Stocks for a Made-in-America Portfolio
The U.S. is starting to look like the least-ugly option in a globe full of uncertainty. If you agree, here are a few concentrated ways to play America.
Winners and Losers in Obama’s Second Term
Some companies are thrilled to see Obama return, others not so much. Here are the healthcare, finance, defense and gun stocks that will react and why.
Wait for a Pullback Before Buying ISRG
Despite everything there is to like about Intuitive Surgical, it'd be foolish to buy right after its hot run -- history says you'll get it for cheaper soon.
Flu’s Pain Is All Gain for These Companies
As this year's flu season intensifies, so do the profits for some businesses such as vaccine makers, pharmacies and even certain food and beverage makers.
OPKO Health’s Healthy Buyout Binge
This healthcare name is rapidly building up a business worth watching. And the possibility of OPKO itself getting bought out isn't too remote.
Surprise! Dendreon Doesn’t Stink Anymore
It took three years, but this biotech may be quietly finding its footing as its innovative Provenge prostate-cancer fighter gains credibility.
Why Pfizer Has to Buy Agila Injectable Drugs
A quick infusion of generic drugs -- via India's Agila Specialties -- could lessen the blow from Pfizer's expiring patents.
Biotech Movers: Dendreon Pops, ArQule Drops
An analyst upgrade on DNDN lifted the shares 21% last Friday, but mid-stage trial failure of a colorectal drug sank ARQL 11% the same day.
Now That the Vivus Dust Has Settled …
The diet-drug maker deserves a second -- more optimistic -- look after the hype and unmeetable expectations have passed.
4 Reasons Celgene Is the Real Deal
Celgene has reached all-time highs in the wake of the firm’s boffo reviews at this week’s JPMorgan Healthcare Conference ... and it's still worth buying.
Alcoa: From Bellwether to Red Herring
Alcoa's fourth-quarter earnings expectations look rosy -- which is better than you can say for the broader market
Flu Season: Where Investors Can Find Relief
This year's flu looks particularly troublesome, but that's good new for the many companies that benefit from flu sufferers' ills. Here's a look at some of them.
Mylan Has the Rx for Portfolio Growth
Warning: Possible side effects of owning this pharmaceutical stock include outsized portfolio growth.
